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The E3 ubiquitin ligase cbl-b has been identified as an
important gatekeeper limiting T cell activation and more
recently also NK cell activation. Hence, cbl-b deficient NK
cells displayed stronger anti-tumor responses and this has
been linked to a key role of cbl-b for modulation of TAM-
receptors. However, in T cells cbl-b has been described to
interact with different key regulators of T cell receptor
and costimulatory signaling pathways. We have therefore
investigated, whether abrogation of cbl-b function in
human NK cells mediates increased responsiveness to
cytokine stimulation.
Primary human NK cells were isolated and cbl-b
silenced by electroporation with siRNA directed against
cbl-b. Cbl-b silenced NK cells reacted stronger to tumor
cell contact and this response was synergistically enhanced
by cytokine stimulation with IL-2 and IL-12. Moreover,
stimulation of cbl-b silenced NK cells with cytokines in
the absence of tumor cells, either with IL-2 and IL-12 or
IL-2 alone led to enhanced activation of NK cells, resulting
in increased secretion of effector cytokines like IFN-g and
TNF-a and upregulation of the activation marker CD69.
Similar results were obtained for stimulation of cbl-b
silenced T cells with other key cytokines of innate immune
responses, particularly type I Interferons like IFN-a and
IFN-b. These data demonstrate that the proposed central
role of cbl-b as a negative regulator of various signaling
pathways, including Akt, also applies to NK cells.
Together, these results show that interfering with cbl-b
function in human NK cells enables synergistic responses
to key cytokines of innate and adaptive immune responses.
Thus, targeting cbl-b in the context of tumor-immune
therapy should not be confined to the T cell compartment,
but include NK cells as well. This can be achieved in the
context of adoptive cell therapies, when autologous patient
PBMCs are silenced for cbl-b ex vivo and retransferred
afterwards. Such a protocol was established and is cur-
rently tested in a Phase I trial at Wake Forest University.
The observed synergism of cbl-b silencing and NK cell
stimulation by cytokines like IL-2 could be of particular
relevance when tumor-reacting cbl-b silenced T cells
infiltrate the tumor and secrete enhanced amounts of
IL-2. In addition, it also provides a rationale for combina-
tions of cbl-b targeting approaches with local application
of cytokines at the tumor site (e.g. intratumoral injection
of IL-2).
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